Human resources coordinator [h1.location_city]

Job Description

Job Description

Salary : $33.00 - $43.00 Per Hour

Reporting to the Senior Director of Human Resources, this individual will play a critical role in assisting with the day-to-day Human Resources of a public biotechnology company. The Human Resources Coordinator will assist in a number of areas, including but not limited to HR Operations, Compensation & Benefits, Employee Lifecycle and Talent Acquisition. This role features administrative work and coordination with other departments. It consists of accuracy, timeliness and a generalist mindset.

Elicio (ELTX) is a growing organization based out of the Seaport area of Boston, Massachusetts, with additional staff functioning in a virtual-based environment from the Greater Boston area and throughout the United States.

Major Duties / Responsibilities

HR Operations & Administration

• Act as the initial point of contact on HR-related inquiries from employees
• Assist in communicating and ensuring consistent application of Company policies
• Monitor the Companys Human Resources Information System (HRIS) to ensure accuracy of employee files
• Answer employee requests in a quick and accurate manner
• Manage the Companys HRIS to ensure that employee resources are easily accessible and up-to-date
• Conduct daily HR administrative tasks and duties

Compensation & Benefits

Employee Lifecycle

Talent Acquisition

Other projects and duties as are needed.

Education & Professional Experience

Required :

Preferred :

Working Days :

This is a full-time, contractor role to start. Working days are Monday through Friday

Working Conditions : Busy office / laboratory environment with frequent deadlines and interruptions

Travel : Travel is not required

Physical Requirements : Subject to periods of sitting or standing, vision is required to monitor data.

Work Location : This role is hybrid, with the ability to work onsite 2 3 days per week and remotely on the other days

About Elicio Therapeutics

Elicio Therapeutics, Inc. (Nasdaq : ELTX) is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of high-prevalence cancers, including mKRAS-positive pancreatic and colorectal cancers. Elicio intends to build on recent clinical successes in the personalized cancer immunotherapy space to develop effective, off-the-shelf immunotherapies. Elicios Amphiphile (AMP) technology aims to enhance the education, activation and amplification of cancer-specific T cells relative to conventional immunotherapy strategies, with the goal of promoting durable cancer immunosurveillance in patients. Elicios ELI-002 lead program is an off-the-shelf immunotherapy candidate targeting the most common KRAS mutations, which drives approximately 25% of all solid tumors. Off-the-shelf immunotherapy approaches have the potential benefits of low cost, rapid commercial scale manufacturing, and rapid availability of drug to patients especially in neo-adjuvant settings and for prophylaxis in high-risk patients, contrary to personalized immunotherapy approaches. ELI-002 is being studied in an ongoing, randomized clinical trial in patients with mKRAS-positive pancreatic cancer who completed standard therapy but remain at high risk of relapse. ELI-002 also has been studied in patients with mKRAS-positive colorectal cancer (CRC) in Phase 1 studies. The updated AMPLIFY-201 Phase 1 data for PDAC and CRC was presented at the ESMO Immuno-Oncology Congress 2024 and included a 16.3-month median recurrence-free survival and 28.9-month median overall survival for the full study population. In the future, Elicio plans to expand ELI-002 to other indications including mKRAS positive lung cancer and other mKRAS positive cancers. Elicios pipeline includes additional off-the-shelf therapeutic cancer immunotherapy candidates, including ELI-007 and ELI-008, that target BRAF-driven cancers and p53 hotspot mutations, respectively. For more information, please visitwww.elicio.com.

About the Amphiphile Platform

Elicios proprietary AMP platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Elicio believes this site-specific delivery of disease-specific antigens, adjuvants and other immunomodulators may efficiently educate, activate and amplify critical immune cells, potentially resulting in induction and persistence of potent adaptive immunity required to treat many diseases. In pre-clinical models, Elicio observed lymph node-specific engagement driving therapeutic immune responses of increased magnitude, function and durability. Elicio believes its AMP lymph node-targeted approach will produce superior clinical benefits compared to immunotherapies that do not engage the lymph nodes based on preclinical studies.

Elicios AMP platform, originally developed at the Massachusetts Institute of Technology, has broad potential in the cancer space to advance a number of development initiatives through internal activities, in-licensing arrangements or development collaborations and partnerships.

The AMP platform has been shown to deliver immunotherapeutics directly to the lymph nodes by latching on to the protein albumin, found in the local injection site, as it travels to lymphatic tissue.

Compensation : $33.00 - $43.00 per hour dependent upon experience and relevant qualifications

THIS IS A CONTRACTOR ROLE TO START